These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 14998422)

  • 1. Concentration-time profile for perhexiline and hydroxyperhexiline in patients at steady state.
    Jones TE; Morris RG; Horowitz JD
    Br J Clin Pharmacol; 2004 Mar; 57(3):263-9. PubMed ID: 14998422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determination of perhexiline and its metabolite hydroxyperhexiline in human plasma by liquid chromatography/tandem mass spectrometry.
    Zhang M; Moore GA; Barclay ML; Begg EJ
    J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Oct; 877(27):3025-30. PubMed ID: 19646935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of the antianginal agent perhexiline: relationship between metabolic ratio and steady-state dose.
    Sallustio BC; Westley IS; Morris RG
    Br J Clin Pharmacol; 2002 Aug; 54(2):107-14. PubMed ID: 12207628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of perhexiline and hydroxyperhexiline in plasma by liquid chromatography-mass spectrometry.
    Beck O; Stephanson N; Morris RG; Sallustio BC; Hjemdahl P
    J Chromatogr B Analyt Technol Biomed Life Sci; 2004 Jun; 805(1):87-91. PubMed ID: 15113543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetics of perhexiline from very sparse, routine monitoring data.
    Hussein R; Charles BG; Morris RG; Rasiah RL
    Ther Drug Monit; 2001 Dec; 23(6):636-43. PubMed ID: 11802096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Steady-state pharmacokinetics of the enantiomers of perhexiline in CYP2D6 poor and extensive metabolizers administered Rac-perhexiline.
    Davies BJ; Herbert MK; Coller JK; Somogyi AA; Milne RW; Sallustio BC
    Br J Clin Pharmacol; 2008 Mar; 65(3):347-54. PubMed ID: 17875193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perhexiline.
    Ashrafian H; Horowitz JD; Frenneaux MP
    Cardiovasc Drug Rev; 2007; 25(1):76-97. PubMed ID: 17445089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between plasma perhexiline concentration and symptomatic status during short-term perhexiline therapy.
    Stewart S; Voss DW; Northey DL; Horowitz JD
    Ther Drug Monit; 1996 Dec; 18(6):635-9. PubMed ID: 8946658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of CYP2D6 genotype on trough plasma perhexiline and cis-OH-perhexiline concentrations following a standard loading regimen in patients with myocardial ischaemia.
    Davies BJ; Coller JK; James HM; Somogyi AA; Horowitz JD; Sallustio BC
    Br J Clin Pharmacol; 2006 Mar; 61(3):321-5. PubMed ID: 16487226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical inhibition of CYP2D6-catalysed metabolism by the antianginal agent perhexiline.
    Davies BJ; Coller JK; James HM; Gillis D; Somogyi AA; Horowitz JD; Morris RG; Sallustio BC
    Br J Clin Pharmacol; 2004 Apr; 57(4):456-63. PubMed ID: 15025744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction of terbinafine (anti-fungal agent) with perhexiline: a case report.
    Sheikh AR; Westley I; Sallustio B; Horowitz JD; Beltrame JF
    Heart Lung Circ; 2014 Jun; 23(6):e149-51. PubMed ID: 24373912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of aging, renal dysfunction, left ventricular systolic impairment, and weight on steady state pharmacokinetics of perhexiline.
    Ling LH; Chik W; Averbuj P; Pati PK; Sverdlov AL; Ngo DT; Morris RG; Sallustio BC; Horowitz JD
    Ther Drug Monit; 2011 Apr; 33(2):251-6. PubMed ID: 21383654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perhexiline maleate treatment for severe angina pectoris--correlations with pharmacokinetics.
    Horowitz JD; Sia ST; Macdonald PS; Goble AJ; Louis WJ
    Int J Cardiol; 1986 Nov; 13(2):219-29. PubMed ID: 3793279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of CYP2D6 metabolizer status on the disposition of the (+) and (-) enantiomers of perhexiline in patients with myocardial ischaemia.
    Inglis SC; Herbert MK; Davies BJ; Coller JK; James HM; Horowitz JD; Morris RG; Milne RW; Somogyi AA; Sallustio BC
    Pharmacogenet Genomics; 2007 May; 17(5):305-12. PubMed ID: 17429312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between plasma, atrial and ventricular perhexiline concentrations in humans: insights into factors affecting myocardial uptake.
    Drury NE; Licari G; Chong CR; Howell NJ; Frenneaux MP; Horowitz JD; Pagano D; Sallustio BC
    Br J Clin Pharmacol; 2014 May; 77(5):789-95. PubMed ID: 24117487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can Perhexiline Be Utilized Without Long-Term Toxicity? A Clinical Practice Audit.
    Phuong H; Choi BY; Chong CR; Raman B; Horowitz JD
    Ther Drug Monit; 2016 Feb; 38(1):73-8. PubMed ID: 26309031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Method for the analysis of perhexiline and its hydroxy metabolite in plasma using high-performance liquid chromatography with precolumn derivatization.
    Grgurinovich N
    J Chromatogr B Biomed Sci Appl; 1997 Aug; 696(1):75-80. PubMed ID: 9300911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of interlaboratory performance in the provision of perhexiline therapeutic drug monitoring services in Australia.
    Sallustio BC; Morris RG
    Ther Drug Monit; 1999 Aug; 21(4):389-94. PubMed ID: 10442691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic review of the efficacy and safety of perhexiline in the treatment of ischemic heart disease.
    Killalea SM; Krum H
    Am J Cardiovasc Drugs; 2001; 1(3):193-204. PubMed ID: 14728034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perhexiline--stable plasma concentrations with formulation change.
    Siebert WJ; Gabb GM; Wing LM
    Aust N Z J Med; 1996 Oct; 26(5):707-8. PubMed ID: 8958370
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.